Showing 51-60 of 4131 results for "".
Dr. Eichenfield Urges Caution for Steroid-Phobia at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-eichenfield-urges-caution-for-steroid-phobia-at-maui-derm/32919/In addition to the various clinical skin conditions that pediatric patients present with, dermatologists now must understand how to deal with steroid-phobia, according to Lawrence Eichenfield, MD.Journal Club: Colloidal Oat for Prevention and Treatment
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-colloidal-oat-for-prevention-and-treatment/32407/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Lawrence Eichenfield, MD, FAAD, discuss a study demonstrating the benefits of oat for infant skincare, especially for the treatment and mitigation of atopic dermatitis.Advances in Topicals for Skin Conditions
https://practicaldermatology.com/topics/psoriasis/advances-in-topicals-for-skin-conditions/20197/There are more topicals available today than ever before for acne, rosacea, and psoriasis, and even more are coming down the pike. Larry Green, MD, reviews the current topical landscape in dermatology and previews what’s in the pipeline.Journal Club: Biologics for Young Children
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-biologics-for-young-children/32400/Practical Dermatology Editorial Board member Lawrence Eichenfield, MD, FAAD, Dawn Eichenfield, MD, PhD, discuss the article "Biologic therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations," from Expert Opinion on Drug Safety. RExciting Developments in Treating Pediatric Dermatology
https://practicaldermatology.com/conferences/maui-derm-2024/exciting-developments-in-treating-pediatric-dermatology/20246/Chief Medical Editor Neal Bhatia, MD and Lawrence Eichenfield, MD, discuss the range of therapies currently approved or in the pipeline for atopic dermatitis, pruritus, pediatric acne--and the importance of messaging on TikTok.Interoperability Redux
https://practicaldermatology.com/topics/practice-management/interoperability-redux/20455/Is the new push for interoperability déjà vu all over again?How to Deal with Hagglers and Other Tough Patients
https://practicaldermatology.com/topics/practice-management/how-to-deal-with-hagglers-and-other-tough-patients/19211/Michael J. Sacopulos, JD offers strategies for handling difficult patients and how to negotiate with hagglers.TELEMEDICINE AND ONLINE PRESENCE
https://practicaldermatology.com/topics/practice-management/matv-sacopulos-2--ahooremm/19114/Is telemedicine the next wave of medical practice? Michael J. Sacopulos, JD (www.medriskinstitute.com) weighs in.Burnout: Is Personal Happiness the Answer?
https://practicaldermatology.com/programs/practical-dermatology/burnout-is-personal-happiness-the-answer/18191/Physician burnout remains a conversation, and the pandemic dramatically changed the landscape for dermatologists—for better and for worse. Omaha, NE-based Joel Schlessinger, MD, who serves as Chief Cosmetic Surgery Editor of Practical Dermatology® speaks with Las Vegas-based dermatologist H.L. GreenDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global P